Repsol SA will develop 1,768 MW of renewable energy projects in Italy, which includes 943 MW of wind and 825 MW of solar projects, with more than 60% of them at an advanced stage of development.
Italy is one of the countries Repsol is focusing on in its international renewables expansion.
The Spanish energy group, which already has an office in Milan, will soon start constructing its first two photovoltaic arrays in Italy with a capacity of 11 MW.
Repsol has amassed the portfolio by acquiring several projects combined with the Italian sites of Asterion Energies, which Repsol bought recently, adding a 7,700-MW pipeline.
Repsol is targeting 6,000 MW of installed renewables capacity by 2025 and 20,000 MW by 2030. Currently, it has more than 2,000 MW in operation, including 1,600 MW in Spain.


How is Antarctica melting, exactly? Crucial details are beginning to come into focus
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
LA fires: Long-term exposure to wildfire smoke is poorly understood − and a growing risk
As the Black Summer megafires neared, people rallied to save wildlife and domestic animals. But it came at a real cost
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
South Korea’s Weak Won Struggles as Retail Investors Pour Money Into U.S. Stocks
An unexpected anomaly was found in the Pacific Ocean – and it could be a global time marker
Fed Governor Lisa Cook Warns Inflation Risks Remain as Rates Stay Steady
Vietnam’s Trade Surplus With US Jumps as Exports Surge and China Imports Hit Record
Trump Endorses Japan’s Sanae Takaichi Ahead of Crucial Election Amid Market and China Tensions
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
What’s so special about Ukraine’s minerals? A geologist explains
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains
How ongoing deforestation is rooted in colonialism and its management practices
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns 



